LOAN AGREEMENTLoan Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
THIS LOAN AGREEMENT (this “Loan Agreement”) dated effective as of September 8, 2017 (the “Effective Date”) is made and executed by and between Jain Investments, LLC, a Texas limited liability company (the “Lender”) and Arog Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is made and entered into effective as of January 5, 2015 (the “Effective Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Seller”), and Videra Pharmaceuticals, LLC a Delaware limited liability company ( “Buyer”). Seller and Buyer are sometimes referred to herein as the “Parties,” and each, a “Party.”
MASTER SERVICES AGREEMENTMaster Services Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Master Services Agreement (“Agreement”), is effective June 12, 2018 (the “Effective Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 5420 LBJ Freeway, Suite 410, Dallas TX 75240 (“Recipient”), and Jain Investments, LLC,, a Texas limited liability company having a principal place of business at or address at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240 (“Provider”). Recipient and Provider may be referred to herein individually as a “Party” or, collectively, as the “Parties.”
First Amendment to the January S, 2015, License Agreement between AROG Pharmaceuticals, Inc. and Videra Pharmaceuticals, LLCLicense Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment (“Amendment”), dated June 22, 2018, (the “Amendment Effective Date”) is made by and between AROG Pharmaceuticals, Inc., (hereinafter referred to as “Company”), with a place of business at 5420 LBJ Freeway, Ste. 410, Dallas, Texas 75240, United States, and Videra Pharmaceuticals, LLC (hereinafter referred to as “Licensee”), with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, United States. Company and Licensee are each individually referred to herein as a “Party” and collectively as the “Parties.”
CLINICAL RESEARCH ORGANIZATION MASTER SERVICES AGREEMENTMaster Services Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Clinical Research Organization Master Services Agreement (“Agreement”), is effective June 12, 2018 (the “Effective Date”), by and between AROG PHARMACEUTICALS, INC., a Delaware corporation, having a principal place of business at 5420 LBJ Freeway, Suite 410, Dallas TX 75240 (“Sponsor”), and DAVA ONCOLOGY, LP D/B/A DAVA CRO SERVICES, having a principal place of business at or address at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240 (“CRO”). Sponsor and CRO may be referred to herein individually as a “Party” or, collectively, as the “Parties”.
LICENSE AGREEMENTLicense Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is entered into and made effective as of January 5, 2015 (“Effective Date”) by and between Arog Pharmaceuticals Inc., a Delaware corporation having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 (“Company”) and Videra Pharmaceuticals, LLC, a Delaware limited liability company having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 (“Licensee”). Licensee and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
First Amendment to the April 11, 2018 Loan Agreement between AROG Pharmaceuticals, Inc. and Jain Investments, LLCLoan Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment (“Amendment”), dated May 30, 2018, is made by and between AROG Pharmaceuticals, Inc. (the “Borrower”), with a place of business at 5420 LBJ Freeway, Suite. 410, Dallas, Texas 75240, and Jain Investments, LLC (the “Lender”), with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240.
STOCK PURCHASE AND DEBT CONVERSION AGREEMENTStock Purchase and Debt Conversion Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Stock Purchase and Debt Conversion Agreement (the “Agreement”) is made and entered into as of January 31, 2017 (the “Effective Date”) by and between Arog Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Jain Investments LLC, a Texas limited liability company (the “Purchaser”). Capitalized terms not otherwise defined herein shall have the meanings assigned thereto in the Company’s Bylaws adopted pursuant to the Company’s Agreement and Plan of Conversion, effective September 30, 2014 (the “Bylaws”).
LICENSE AGREEMENTLicense Agreement • September 24th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
